The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
T5 Data Centers Strategic Partnership
Advised T5 Data Centers, a leading national data center owner and operator, on the creation of a fully integrated platform with QuadReal Property Group to develop, acquire and operate data centers via a $1.0 billion investment from QuadReal
Blu Pagamentos
Advised Blu Pagamentos, a high-growth Brazilian B2B cash management fintech firm, on the sale of a minority stake
Hitachi's Automotive Lithium-Ion Battery Business
Advised Hitachi, a leading global industrial conglomerate, on the sale of its LiB business including Hitachi Vehicle Energy
Pfizer Inc. Consumer Health Business
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
Assets owned by GlaxoSmithKline plc
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
Long-term lithium hydroxide offtake agreement with Mitsui & Co.
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a lithium hydroxide offtake agreement with Mitsui & Co., a leading global marketing and trading conglomerate based in Japan. The agreement is for an initial term of two years, plus two 2-year term extension options
Common shares and common share purchase warrants in Canopy Growth
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
Martabe gold and silver mine
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
Park Electrochemical (Electronics Business)
Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
IslaLink
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
Cityfibre Infrastructure Holdings plc
Advised Antin Infrastructure Partners and West Street Infrastructure Partners, part of Goldman Sachs’ Merchant Banking division, in connection with the take private of CityFibre Infrastructure Holdings plc, a leading independent provider of wholesale fibre network infrastructure
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
Lonmin
Advising Lonmin PLC, a major fully integrated producer of Platinum Group Metals, on the amendment of its debt facilities to support the review and implementation of its strategic options
Pure Industrial Real Estate Trust
Advised the Special Committee of the Board of Trustees of Pure Industrial Real Estate Trust ("PIRET"), the largest pure-play industrial REIT in Canada, regarding the acquisition of PIRET by Blackstone Property Partners
London & Country Mortgages Limited (“L&C”)
Advised Experian plc, the world’s leading global information services company, in connection with the acquisition of a 25% stake in L&C, the UK’s largest fee free mortgage adviser
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
Wells Fargo Share Registration & Service business
Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue
Chromalox
Advised Chromalox, a leading provider of electrical products, systems and solutions for industrial process heating and temperature management, on its sale to Spirax Sarco, a global engineering group
Equity stake in Bupa Arabia
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
Cheetahmail
Advised Vector Capital on the acquisition of Cheetahmail from Experian plc
LCH.Clearnet SA
Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated
Host Europe Group
Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process